La Jolla Pharmaceutical Company (LJPC) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
201 JONES ROAD, SUITE 400 WALTHAM, MA 02451 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 44,600 | 46,765 | 45,888 | 38,634 | 21,221 | ||||
| Cash and cash equivalents | 44,169 | 46,765 | 45,888 | 38,634 | 21,221 | ||||
| Short-term investments | 390 | ||||||||
| Other undisclosed cash, cash equivalents, and short-term investments | 41 | ||||||||
| Receivables | 5,729 | 8,793 | 8,596 | 4,153 | 5,834 | ||||
| Inventory, net of allowances, customer advances and progress billings | 7,113 | 6,094 | 5,481 | 5,374 | 6,013 | ||||
| Inventory | 7,113 | 6,094 | 5,481 | 5,374 | 6,013 | ||||
| Prepaid expense | 359 | 28 | 263 | 319 | 505 | ||||
| Other undisclosed current assets | 5,118 | 4,235 | 4,938 | 5,785 | 2,883 | ||||
| Total current assets: | 62,919 | 65,915 | 65,166 | 54,265 | 36,456 | ||||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 275 | 367 | 419 | 490 | 536 | ||||
| Property, plant and equipment | 88 | 140 | 163 | 186 | 215 | ||||
| Intangible assets, net (including goodwill) | 33,056 | 33,832 | 34,220 | 34,608 | 34,996 | ||||
| Goodwill | 20,123 | 20,123 | 20,123 | 20,123 | 20,123 | ||||
| Intangible assets, net (excluding goodwill) | 12,933 | 13,709 | 14,097 | 14,485 | 14,873 | ||||
| Restricted cash and investments | 40 | 40 | 40 | 40 | 40 | ||||
| Total noncurrent assets: | 33,459 | 34,379 | 34,842 | 35,324 | 35,787 | ||||
| TOTAL ASSETS: | 96,378 | 100,294 | 100,008 | 89,589 | 72,243 | ||||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 7,086 | 15,835 | 15,933 | 11,512 | 12,134 | ||||
| Employee-related liabilities | ✕ | 1,801 | 1,912 | 1,693 | 2,878 | ||||
| Accounts payable | 2,789 | 2,314 | 1,846 | 1,098 | 2,762 | ||||
| Accrued liabilities | 4,297 | 11,720 | 12,175 | 8,721 | 6,494 | ||||
| Deferred revenue | 2,849 | ||||||||
| Other undisclosed current liabilities | 6,113 | 160 | 168 | 196 | 204 | ||||
| Total current liabilities: | 16,048 | 15,995 | 16,101 | 11,708 | 12,338 | ||||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 120 | 208 | 251 | 294 | 332 | ||||
| Liabilities, other than long-term debt | 4,523 | 4,493 | 4,568 | 4,112 | |||||
| Other liabilities | 4,523 | 4,493 | 4,568 | 4,112 | |||||
| Operating lease, liability | 120 | 208 | 251 | 294 | 332 | ||||
| Other undisclosed noncurrent liabilities | 150,584 | 147,976 | 146,606 | 145,337 | 143,548 | ||||
| Total noncurrent liabilities: | 150,824 | 152,707 | 151,350 | 150,199 | 147,992 | ||||
| Total liabilities: | 166,872 | 168,702 | 167,451 | 161,907 | 160,330 | ||||
| Equity | |||||||||
| Equity, attributable to parent, including: | (70,494) | (68,408) | (67,443) | (72,318) | (88,087) | ||||
| Common stock | 3 | 3 | 3 | 3 | 3 | ||||
| Additional paid in capital | 982,687 | 988,544 | 987,249 | 986,107 | 984,756 | ||||
| Accumulated deficit | (1,057,090) | (1,060,861) | (1,058,601) | (1,062,334) | (1,076,752) | ||||
| Other undisclosed equity, attributable to parent | 3,906 | 3,906 | 3,906 | 3,906 | 3,906 | ||||
| Total equity: | (70,494) | (68,408) | (67,443) | (72,318) | (88,087) | ||||
| TOTAL LIABILITIES AND EQUITY: | 96,378 | 100,294 | 100,008 | 89,589 | 72,243 | ||||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 10,425 | (63,510) | 13,314 | 16,059 | 34,137 | 10,951 | ||
| Cost of revenue | (1,782) | (2,472) | (1,756) | (5,943) | (3,806) | |||
| Cost of goods and services sold | (850) | (3,806) | ||||||
| Gross profit: | 8,643 | 10,842 | 14,303 | 28,194 | 7,145 | |||
| Operating expenses | (10,689) | (10,317) | (10,510) | (10,701) | (10,535) | |||
| Operating income (loss): | (2,046) | 525 | 3,793 | 17,493 | (3,390) | |||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 543 | (25) | 80 | (450) | 366 | |||
| Interest and debt expense | (2,402) | (2,729) | (2,672) | (2,609) | (2,649) | |||
| Income (loss) from continuing operations before equity method investments, income taxes: | (3,905) | (2,229) | 1,201 | 14,434 | (5,673) | |||
| Other undisclosed income from continuing operations before income taxes | 3,908 | 2,532 | 2 | |||||
| Income (loss) from continuing operations before income taxes: | 3 | (2,229) | 3,733 | 14,436 | (5,673) | |||
| Income tax expense | (1) | (31) | (18) | |||||
| Income (loss) from continuing operations: | 2 | (2,260) | 3,733 | 14,418 | (5,673) | |||
| Income (loss) before gain (loss) on sale of properties: | 2 | ✕ | (2,260) | 3,733 | 14,418 | (5,673) | ||
| Net income (loss): | 2 | (2,260) | 3,733 | 14,418 | (5,673) | |||
| Other undisclosed net income attributable to parent | 2,195 | |||||||
| Net income (loss) available to common stockholders, diluted: | 2 | (2,260) | 3,733 | 14,418 | (3,478) | |||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 2 | (2,260) | 3,733 | 14,418 | (5,673) | |||
| Comprehensive income (loss), net of tax, attributable to parent: | 2 | (2,260) | 3,733 | 14,418 | (5,673) | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.